{"id":51605,"date":"2024-07-09T11:52:44","date_gmt":"2024-07-09T11:52:44","guid":{"rendered":"https:\/?p=51605"},"modified":"2024-07-09T11:52:44","modified_gmt":"2024-07-09T11:52:44","slug":"gilead-stock-rebound-potential-despite-recent-slide","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/gilead-stock-rebound-potential-despite-recent-slide\/","title":{"rendered":"Gilead Stock: Rebound Potential Despite Recent Slide"},"content":{"rendered":"

Biopharmaceutical giant Gilead Sciences (GILD)<\/a> has seen its share price drop nearly 20% in the past six months. However, recent developments suggest a potential turnaround could be on the horizon.<\/span><\/p>\n

 <\/p>\n

Pipeline Progress Fuels Optimism:\u00a0<\/strong><\/h2>\n

Gilead boasts a robust pipeline of drugs in development, targeting a range of therapeutic areas. This consistent progress is a positive indicator for the company’s future growth potential. Investors are particularly interested in advancements in areas like oncology and HIV, which could lead to significant revenue streams.<\/span><\/p>\n

\"GILD<\/a><\/p>\n

Stock Target Advisor\u2019s Analysis on Gilead:\u00a0<\/strong><\/h2>\n

Stock Target Advisor maintains a ‘Buy’ stock rating on Gilead, though, intriguingly, it projects no price change over the next 12 months. <\/span>From the 21 covering analysts, Gilead has earned an average ‘Buy’ rating with an average target price set at $82.93. The maximum price target set by analysts reaches $105, while the lowest aims for $65.<\/span><\/p>\n

 <\/p>\n

Trailing 12 Months Returns Analysis:\u00a0<\/strong><\/h2>\n

Over the past one year, the capital gain has decreased by 10.75%, landing it in the 55.56th percentile within its sector. Simultaneously, the dividend return was 2.03%, ranking it in the 25th sector percentile. This combination of capital gains and dividends resulted in a total return of -8.72%, keeping it in the 55.56th percentile of its sector.<\/span><\/p>\n

<\/p>\n

\n
\n

GILD Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n